Enthorin Therapeutics, LLC today announced that it has entered into an option-to-license agreement with Rumi Therapeutics for ENT-7340, Enthorin’s IND-enabled phosphodiesterase 2A (PDE2A) inhibitor being developed for Fragile X syndrome (FXS) and other intellectual and developmental disabilities.

Under the agreement, Rumi Therapeutics will assume responsibility for development of ENT-7340, which will be advanced by Rumi under the development name RTX-7340. Enthorin will receive an upfront payment, milestones, and an option exercise fee. As well as be eligible for development, regulatory and commercial milestone payments, and royalties on future net sales. In addition, Enthorin is providing scientific and technical expertise in collaboration with Rumi for the initial stages of the program’s development.

“ENT-7340 represents years of discovery and development work aimed at translating the biology of PDE2 inhibition into effective therapeutics for the treatment of neurodevelopmental disorders such as Fragile X,” said Marco Peters, Ph.D., Co-Founder and Chief Scientific Officer of Enthorin Therapeutics. “Rumi brings distinctive capabilities for evaluating therapeutics in human cellular and organoid models, providing an opportunity to further validate the biology of RTX-7340 in human systems and explore its mechanism of action in Fragile X syndrome and additional indications. We are excited about this agreement and look forward to supporting Rumi during the initial development phase as they advance the program toward clinical development.”

ENT-7340 selectively inhibits PDE2A, an enzyme regulating both cAMP and cGMP signaling pathways involved in neuronal function and synaptic plasticity. The ongoing program will build on Enthorin’s research implicating disrupted cyclic nucleotide signaling and its role in Fragile X syndrome.

Building on FRAXA’s Contributions to Fragile X Therapeutic Development

Enthorin would like to recognize the important contributions of the FRAXA Research Foundation to the development of the PDE2 program. Through sustained support of basic and translational research, FRAXA has helped advance understanding of the molecular consequences of FMRP loss and establish cyclic nucleotide signaling as a promising therapeutic mechanism in Fragile X. FRAXA has supported Enthorin’s efforts to translate these insights into drug-development programs, contributing to the scientific foundation underlying the company’s work in Fragile X syndrome.

“FRAXA has long supported research aimed at understanding how altered cellular signaling contributes to Fragile X syndrome and how those discoveries can be translated into treatments,” said Michael Tranfaglia, M.D., Medical Director and Co-Founder of FRAXA Research Foundation. “Cyclic nucleotide signaling has emerged as an important part of that biology, and we are pleased to have supported Enthorin’s work in this area. The advancement of RTX-7340 toward clinical development is an encouraging next step in translating this science into potential treatments for people with Fragile X.”

 

Source: businesswire.com

Report Abuse